Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925542 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
A Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT06925542: Recruiting Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by CRISPR Therapeutics.
NCT06925542 is a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 80 participants, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06925542, a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Primary Outcome
Incidence of dose-limiting toxicities
Conditions Studied
Interventions
- BIOLOGICAL CTX112
Study Locations (8)
Other
- Research Site 7 - Augsburg
- Research Site 3 - Hanover
California
- Research Site 4 - Redwood City
Illinois
- Research Site 2 - Chicago
Iowa
- Research Site 8 - Iowa City
Massachusetts
- Research Site 6 - Boston
Missouri
- Research Site 1 - St Louis
North Carolina
- Research Site 5 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 1 |
What NCT06925542 shows while recruiting
NCT06925542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (74% lower).
The record links to 7 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which CTX112 is the first listed.
NCT06925542 lists 8 locations in 7 states (Other, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT06925542 about?
NCT06925542 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease". This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopat...
What is the current status of trial NCT06925542?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-03-10. Estimated completion is 2031-12-31.
What conditions does trial NCT06925542 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, Myositis, SLE (Systemic Lupus).
What interventions are being tested in trial NCT06925542?
The interventions under investigation include: CTX112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06925542?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925542 being conducted?
This trial has 8 study locations across California, Illinois, Iowa, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06925542's enrollment target sits among peer trials
80 16th of 30 higher than 15 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI